Evidence map›Paper›PMID 36277932›Full record

ArticleFrontiers in neurology2022

Risk factors of late lesion growth after acute ischemic stroke treatment.

Praneeta Konduri, Amber Bucker, Anna Boers, Bruna Dutra, Noor Samuels, Kilian Treurniet, Olvert Berkhemer, Albert Yoo, Wim van Zwam, Robert van Oostenbrugge and 7 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Prevalence of "Ghost Infarct Core" after Endovascular Thrombectomy.AJNR. American journal of neuroradiology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Praneeta KonduriDepartment of Biomedical Engineering and Physics, Amsterdam UMC, Location AMC, Amsterdam, Netherlands.
Amber BuckerDepartment of Radiology, University Medical Center Groningen, Groningen, Netherlands.
Anna BoersDepartment of Biomedical Engineering and Physics, Amsterdam UMC, Location AMC, Amsterdam, Netherlands.
Bruna DutraDepartment of Biomedical Engineering and Physics, Amsterdam UMC, Location AMC, Amsterdam, Netherlands.
Noor SamuelsDepartment of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Kilian TreurnietDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location AMC, Amsterdam, Netherlands.
Olvert BerkhemerDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location AMC, Amsterdam, Netherlands.
Albert YooDepartment of Radiology, Texas Stroke Institute, Dallas-Fort Worth, Dallas, TX, United States.
Wim van ZwamDepartment of Radiology and Nuclear Medicine, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, Netherlands.
Robert van OostenbruggeDepartment of Neurology, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, Netherlands.
Aad van der LugtDepartment of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands.
Diederik DippelDepartment of Neurology, Erasmus MC University Medical Center, Rotterdam, Netherlands.
Yvo RoosDepartment of Neurology, Amsterdam UMC, Location AMC, Amsterdam, Netherlands.
Joost BotDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit van Amsterdam, Amsterdam, Netherlands.
Charles MajoieDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location AMC, Amsterdam, Netherlands.
Henk MarqueringDepartment of Biomedical Engineering and Physics, Amsterdam UMC, Location AMC, Amsterdam, Netherlands.
MR CLEAN Trial Investigators (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands)
Amsterdam University Medical Centers · NLErasmus MC · NLMaastricht University · NLMedisch Centrum Haaglanden · NLUniversity Medical Center Groningen · NLVrije Universiteit Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Even days after treatment of acute ischemic stroke due to a large vessel occlusion, the infarct lesion continues to grow. This late, subacute growth is associated with unfavorable functional outcome. In this study, we aim to identify patient characteristics that are risk factors of late, subacute lesion growth. Methods: Patients from the MR CLEAN trial cohort with good quality 24 h and 1-week follow up non-contrast CT scans were included. Late Lesion growth was defined as the difference between the ischemic lesion volume assessed after 1-week and 24-h. To identify risk factors, patient characteristics associated with lesion growth (categorized in quartiles) in univariable ordinal analysis ( Results: In the 226 patients that were included, the median lesion growth was 22 (IQR 10-45) ml. In the multivariable model, lower collateral capacity [aOR: 0.62 (95% CI: 0.44-0.87); Conclusion: Late, subacute, lesion growth occurring between 1 day and 1 week after ischemic stroke treatment is influenced by lower collateral capacity, longer time to treatment, unsuccessful recanalization, and larger midline shift. Notably, these risk factors are similar to the risk factors of acute lesion growth, suggesting that understanding and minimizing the effects of the predictors for late lesion growth could be beneficial to mitigate the effects of ischemia.

Indexed as

acute ischemic strokeinfarct growthlesion evolutionpost-treatmentpredictorsrisk factorssubacute

Identifiers

PMID36277932
PMCPMC9581245
OpenAlexW4301585141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.